Switching bio's for psoriasis a review

[Fred]

Investigating the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic.

Quote:

---

Question: 
What is the effectiveness and safety of interclass biopharmaceutical switching in psoriasis treatment?

Findings:
This systematic review and meta-analysis of 24 randomized clinical trials including 12 661 patients found that interclass biopharmaceutical switching demonstrated faster short-term and more stable long-term effectiveness. Switching from anti−tumor necrosis factor (TNF)-α agents to anti−interleukin (IL)-23p19 agents and from anti−IL-12/23p40 agents to anti−IL-23p19 agents led to significantly improved effectiveness; however, switching was associated with an increased risk of infection that was higher when switching from anti−TNF-α agents to anti−IL-23p19, anti−IL-17A, and anti−IL-12/23p40 agents.

Meaning: 
These findings indicate that clinicians may consider biopharmaceutical switching to reduce costs, enhance effectiveness, and minimize adverse events; however, future studies are needed to determine the long-term safety of biologics that target different pathways in clinical practice.

[thread=77]

Source: jamanetwork.com

*Funding: Unknown